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Abstract HIVcaninfectthebrainandimpaircentral nervous
system (CNS) function. Combination antiretroviral therapy
(cART) has not eradicated CNS complications. HIV-
associatedneurocognitivedisorders(HAND)remaincommon
despite cART, although attenuated inseverity. This may result
from a combination of factors including inadequate treatment
of HIV reservoirs such as circulating monocytes and glia,
decreasedeffectivenessofcARTinCNS,concurrentillnesses,
stimulant use, and factors associated with prescribed drugs,
including antiretrovirals. This review highlights recent inves-
tigations of HIV-related CNS injury with emphasis on cART-
era neuropathological mechanisms in the context of both US
and international settings.
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Introduction
HIV is neurovirulent, with clinically relevant central
nervous system (CNS) symptoms observed in more than
50% of patients not receiving combination antiretroviral
therapy (cART) [1￿]. The introduction of antiretroviral
therapies more than a decade ago resulted in profound
declines in morbidity and mortality and raised hopes for the
eradication of CNS complications. While the prevalence of
opportunistic infections decreased markedly, HIV-
associated neurocognitive disorders (HAND) remain fre-
quent, although often not diagnosed and typically with
milder symptoms [1￿]. These more subtle forms of HAND
can greatly impact daily functioning and predict non-CNS
morbidity and mortality [2].
Blood tests such as CD4+ lymphocyte counts and
plasma HIV RNA levels are typically used in clinical
settings to estimate the severity of HIV disease and cART
effectiveness. Except in the face of dementia, the impact of
HIVon cognition and the assessment of cART effectiveness
in the CNS have not typically entered into decisions of
when to start therapies or which drugs to start in clinical
settings. Recently, several aspects of this paradigm have
been challenged, including consideration for CNS-specific
effectiveness into therapeutic decision making, the role of
inadequately treated peripheral reservoirs, and the potential
need for more complete suppression of inflammatory
pathways. Antiretroviral side effects including metabolic
derangements may impact brain function. The convergence
of aging and HIV have CNS implications, raising the
possibility of accelerated neurodegenerative syndromes.
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profiles and effectiveness against resistant virus means that
most patients who are adherent can suppress HIV RNA in
plasma. To best inform future treatment options, research
should more purely focus on neuropathological mecha-
nisms of CNS injury in the setting of suppressed HIV RNA
in plasma. This review emphasizes such studies.
Epidemiology and Clinical Manifestations of CNS
Injury in the Era of cART
The proportion of individuals with cognitive impairment by
disease stage has not changed over the past two decades,
despite single, double, or triple combination ART intro-
duced over this period. Current estimates find that nearly
50% of HIV patients in the United States demonstrate
neuropsychological testing performance that is below
expectations compared to age, education, gender, and
ethnicity matched normative groups [1￿]. Among these
cases, about half are symptomatic and few meet research
classification of dementia. Cognitive impairment has been
identified in all international settings where it has been
investigated; yet the prevalence of HAND varies consider-
ably by region. Much of the variability can be explained by
disease stage, treatment, and the instruments used to detect
impairment. Region-specific characteristics seem to be
important also, including the types of coexisting morbid-
ities and the HIV subtypes that are prevalent [3].
In 2007, a consensus panel redefined research diagnostic
categories of HAND, identifying HIV-associated dementia
(HAD) as the most severe form of injury (Table 1). Mild
neurocognitive disorder (MND) represents a milder form of
impairment that still impacts daily activities of living [4]. A
category termed asymptomatic neurocognitive impairment
(ANI) was introduced to recognize individuals with
impairment on neuropsychological testing who report
functional limitations. Compared to other dementias, such
as Alzheimer’s disease (AD) where collateral sources are
available, HIV+subjects often present without proxy
informants, likely influencing the accuracy of functional
assessments particularly when insight is impaired. Thus, it
is possible that with more accurate estimates of impairment,
ANI cases would qualify as having symptomatic disease.
There are few data to inform the longitudinal outcomes
associated with ANI diagnosis.
While it is tempting to consider that MND is a milder
and earlier stage of HAD, there are no data to suggest that
an HIV patient with MND will universally progress to
HAD. Instead, a fluctuating course may occur with some
patients having improvement with time [4, 5]. Indeed, the
very low prevalence of HAD in the era of cART supports
that HAD is not an inevitable consequence of MND in a
manner seen in typical neurodegenerative syndromes such
as AD. It remains unclear whether the pathologies of MND
and HAD overlap or are distinct. The impact of HIV on
brain function differs somewhat from noninfectious neuro-
degenerative disorders where early disease is often heralded
by focal CNS involvement [6]. In contrast, HIV has a
broader CNS impact with emphasis on deep grey matter
structures and subcortical regions in a manner that under-
scores the clinical syndrome that involves cognitive, motor,
and behavioral manifestations. Apathy and depression are
frequent findings in HIV and correlate to disease markers
and CNS anatomic changes [7, 8]. Motor impairment
remains an identifiable aspect of HAND with increasing
frequency among aged individuals [9].
There are limitations to the currently defined cognitive
schemas. They rely heavily on comprehensive neuropsy-
chological testing; however, the ability to administer these
tests, which can last more than three hours, is impractical
for the busy clinical setting, particularly in low-income
countries. Although brief dedicated instruments such as the
HIV Dementia Scale have been developed, their sensitivity
varies in different reports and by educational status [10].
The 2007 criteria have been primarily applied in research
rather than clinical settings and the long-term clinical
outcomes related to these definitions remain unclear. These
Diagnostic entity Cognitive performance Functional performance
Normal cognition Normal Normal
Asymptomatic
neurocognitive
impairment
Acquired impairment in at
least 2 cognitive domains (<1 SD)
Does not impact daily function
Mild
neurocognitive
disorder
Acquired impairment in at least two
cognitive domains (<1 SD)
Interferes with daily function to at
least a mild degree (eg, work
inefficiency, reduced mental acuity)
HIV-associated
dementia
Acquired impairment in at least 2 domains,
typically in multiple domains with at least
2 domains with severe impairment
(<2 SD)
Marked impact on daily function
Table 1 Research criteria for
HIV-associated neurocognitive
disorders [4]
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tions related to the approach and timing of screening and
highlight the need for longitudinal validation data.
Neuropathology in the Era of cART
HIV quickly enters the brain after initial exposure, probably
through infected monocytes and lymphocytes that cross the
blood brain barrier (BBB). Although neurons are not
infected by HIV, they can be injured via indirect mecha-
nisms, including viral proteins, such as gp120 and tat, and
neurotoxins resulting from the neurological immune re-
sponse. HIV encephalopathy is characterized by gliosis,
microglial nodules, perivascular macrophage accumulation,
and the presence of multinucleated giant cells. Immune
activation (encephalitis) is often out of proportion to the
amount of HIV virus present in the brain. One model of
HIV encephalitis, macaques that have been infected with
simian immunodeficiency virus (SIV) and had their CD8+
T cells depleted, identified a pattern of monocytes traffick-
ing from bone marrow as a correlate to encephalitis with
newly arriving brain macrophages demonstrating recent
transmigration [11￿]. The demonstration that these cells
transition from bone marrow is consistent with an informa-
tive case of HAD in humans where the viral signature in
deep brain structures was most consistent with that in bone
marrow and circulating monocytes and a finding that
peripheral monocytes HIV DNA levels correlate to HAND
in the current era [12, 13]. Together, these data raise
concern that peripheral reservoirs continue to play an active
role in brain injury despite cART.
Reports of the neuropathology of HIV in the era of
cART have been mixed. One study demonstrated a less
aggressive degree of immune activation compared to that
seen in the pre-cART era; however, more than 70% of
autopsy cases had some abnormality [14]. In a separate
study, despite plasma HIV RNA suppression, high levels of
microglial/macrophage activation in the basal ganglia and
hippocampus were seen [15]. In a third series using highly
sensitive assays, HIV RNA was identified in about half of
subjects at autopsy, despite most subjects having access to
cART [16]. The highest concentrations were noted in
caudate nucleus whereas lowest concentrations were noted
in cerebrospinal fluid (CSF), suggesting that HIV RNA
levels in CSF may underestimate HIV replication in brain
tissue. Astrocyte infection occurs, particularly in HAD with
infected astrocytes more typically adjacent to perivascular
macrophages and often harboring latent, nonproductive
virus [17]. Based on in vitro macrophage/astrocytes co-
culture experiments, astrocytes likely play a key role in
immune activation and chemotaxis [18]. Potentially revers-
ible synaptic-dendritic neuronal damage has been described
[19￿￿]. The potential reversibility would be consistent with
clinical findings of fluctuating symptoms and this alterna-
tive mechanism of CNS injury would be parsimonious with
the less aggressive levels of inflammation noted in the
cART era.
Aging and Neurodegenerative Disorders
Age is consistently identified as a risk factor for cognitive
impairment in HIV. As HIV patients age due to successful
treatment paradigms, there is growing concern of acceler-
ated risk for neurodegenerative disorders. In HIV-negative
groups, neurodegenerative disorders are characterized by
abnormal brain tissue protein accumulation including
ubiquitin, amyloid-beta, tau and alpha synuclein. There
is a growing body of knowledge supporting abnormal
brain protein accumulation in HIV. Recent reports note
excess hyper-phosphorylated tau, amyloid, and alpha-
synuclein, particularly in older HIV subjects [20–22]. In
patients without HIV encephalitis, age-associated intracel-
lular amyloid-β staining of pyramidal neurons along
axonal tracts has been described [22]. Levels of CSF
amyloid-β1-42 noted in patients with HAND are similar to
that seen in AD [23].
Whether these changes predispose to neurodegeneration
is unknown. Indeed, novel neurological imaging with the
tracer Pittsburgh compound B (PIB), which binds to
amyloid-β1-42 with specificity for AD-type neuritic plaques
rather than soluble amyloid, oligomers, or diffuse plaques,
did not identify increased amyloid in cognitively normal
HIV subjects [24]. However, this study was completed in
subjects who were younger, conferring a lower overall risk
for AD. Data from other CSF studies further suggest that
the neuropathogenic pathways to CNS injury in HIV have
distinct features compared to those of AD [25].
The Effectiveness of cART in the CNS
The BBB can exclude from the CNS many large molecules,
including numerous medications. Data comparing HIV
RNA responses in CSF and plasma along with knowledge
of individual antiretroviral characteristics support the
concept that antiretrovirals differ in their ability to permeate
the BBB in therapeutic concentrations and have led to the
development of CNS penetration-effectiveness (CPE) esti-
mates [26]. CSF measurements are only a surrogate for
concentrations in the brain and may be over or under
estimates. A postmortem report noted HIV in brain tissue
more frequently than in CSF [16] and one report from an
animal model of SIV encephalitis, a condition most similar
to HIV meningitis, demonstrates CNS improvement despite
56 Curr HIV/AIDS Rep (2011) 8:54–61estimated poor BBB penetration of antiretroviral regimens
[27]. An important note is that cART effectiveness, as
estimated by suppression of HIV RNA in plasma, is likely
the strongest determinant of HIV RNA response in CSF.
There have been reports that the CNS can harbor virus
that is discordant from virus in plasma, supporting the
concept that the CNS environment, including drug pressure,
is distinct from blood and lymphoid tissue. A recent case
series identified 11 patients with new-onset neurologic
symptoms who were found to have CSF levels of HIV
RNA out of proportion to that in plasma [28]. The
investigators modified the cART regimens based on drug
resistance patterns in CSF and on CPE estimates, with the
result that all responded with clinical improvement and
reductions in HIV RNA in CSF. Recent abstracts identified
that CSF HIV RNA may occur despite suppression in
plasma at a rate of between 3% and 10% among treated
individuals [29]. A separate case report of HAD demon-
strated viral evolution in CNS that differed from that in
plasma [30].
While most studies demonstrate that cART with better
CPE is associated with viral suppression in CSF, early
reports on the clinical impact have been mixed. For
example, in a prospective cART initiation observational
study, higher CPE ranks were associated with greater
improvements in neuropsychological performance among
individuals with HAND [31]. In contrast, a similar
prospective study failed to identify a clinical cognitive
benefit to initiating regimens with higher CPE ranks [32].
Among perinatally HIV-infected children, higher CNS-
penetrating regimens were associated with a survival
benefit [33]. Furthermore, there are early data to suggest
that CSF suppression to below 2 copies/mL may have a
cognitive benefit, which may highlight an important clinical
need for more sensitive HIV RNA assay [34].
The observational data to date provide support for
considering drug penetration and neurological effectiveness
data when selecting new cART for people with HAND [35]
but must be applied with more caution when adjusting
stable therapy in people with HAND who have already
achieved viral suppression in plasma with their current
cART. Importantly, these data cannot be applied with
confidence to selection of cART for neurologically asymp-
tomatic individuals for the objective of preventing HAND.
Future research efforts should broadly include systemic
morbidities and adherence since altering treatment regimens
may affect non-CNS outcomes. There is a need for larger
sample sizes and a more uniform scientific approach in
these studies in a manner that supports cross-cohort
comparisons.Severalnewclinicaltrialsareopeningtoaddress
these objectives.
The focus on optimization of cART to reach therapeutic
concentrations in CNS addresses control of HIV replication
inresidentcellsbutdoesnotaddresstheimportantmechanism
of continued transmigration during therapy. Hematopoietic
bone marrow cells likely harbor HIV infection before
releasing cells into circulation [36], and recent findings from
animal models demonstrate movement of SIV-infected, bone
marrow–derived monocytes to the CNS perivascular space
[11￿]. Among cART-treated subjects with suppressed plasma
HIV RNA, low-level HIV DNA infection of peripheral
mononuclear cells correlates to HAND [37] and levels of
HIV DNA in circulating monocytes remain elevated among
impaired subjects 1 year after cART with suppression of
plasma HIV RNA [38]. It is increasingly evident that events
occurring in the earliest days of infection have a profound
immunological impact, possibly altered by early treatment.
Antiretroviral treatment initiation during primary compared
to chronic infection also impacts peripheral HIV DNA
reservoirs, providing some support for potential treatment
options (Fig. 1)[ 39].
Neurological Imaging in the Era of cART
Neuroimaging provides an important contribution in HIV
by distinguishing lesions due to opportunistic infections. To
provide benefit in HAND, an ideal neuroimaging biomarker
should 1) diagnose HIV-related CNS injury; 2) detect pre-
symptomatic changes due to HIV; and 3) assess treatment
effects. In the pre-cART era, numerous studies demonstrat-
ed atrophy particularly within subcortical structures and
with correlation to neuropsychological performance. More
recently, a reduction in cortical thickness has also been
observed [40]. Similar findings have been obtained with
measurements of the lateral ventricles, corpus callosum,
caudate nucleus, and hippocampus [41]. While cART can
lead to improvements in brain volume, some neuronal
injury and atrophy persists even after the introduction of
these medications [42].
New imaging modalities have extended beyond struc-
tural MRI and show promise in HAND. Diffusion tensor
imaging (DTI) measures the microstructural diffusion of
water in the brain, a sensitive measure for injury within
white matter tracts. Abnormalities in DTI are noted in HIV
with clinical correlates, but are also noted in asymptomatic
subjects [7, 43]. Magnetic resonance spectroscopy (MRS)
measures regional changes in brain metabolites, with past
studies demonstrating a reduction in N-acetylaspartate
(NAA), a marker of neuronal loss or damage, and increased
myoinositol (MI), a marker of glial activation. Changes
related to severity of cognitive impairment and a tendency
toward normalization with cART have been described [44].
18F-fluoro-deoxy-glucose positron emission tomography
(18F-FDG-PET) can be used to measure metabolic activity.
A recent study of 38 subjects with suppressed plasma HIV
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frontal metabolic rate by 18F-FDG-PET in over half of the
cases, with correlation to shorter duration of HIV, fewer years
on cART, and higher plasma levels of TNFα and IL-6 [45].
More recently, functional MRI (fMRI) techniques have
been employed to measure blood-oxygen-level dependence
(BOLD) as a marker of brain activation. In addition, arterial
spin-labeled (ASL) can measureregionalperfusion. In HIV, an
inverse correlation has been described between baseline
measurementsofrestingcerebralbloodflow(CBF)anddegree
of neurocognitive impairment with CBF reduced soon after
serocoversion [46]. An effect of both aging and HIV has been
described [47].
Together, these modalities demonstrate continued CNS
abnormality despite cARTand suggest that the most promising
approaches may involve combination multimodal imaging.
Unfortunately, many neuroimaging studies suffer from small
heterogenous samples. Larger multicenter studies that include
use of other biomarkers are needed. Given the resources
r e q u i r e dt oa p p l yi ti nt h ec l i n ic, these neuroimaging bio-
markers may have limited applicability in understanding the
disease in the developing world where HIV is most prevalent.
Other Contributing Factors to Cognitive Impairment
in the Era of cART
Early epidemiological data suggest a multifactorial etiology
to cognitive impairment in the cART era. In addition to the
direct and the indirect consequences of HIV and the
immune response, contributions are most likely to result
from medication effects (both prescription and non-
prescription), coexisting morbid illnesses including cere-
brovascular disease, and infections such as hepatitis C.
There are limited data to further suggest differences in
neuropathogenesis by HIV subtype.
The elevated frequency of dyslipidemia, smoking, and
glucoregulatory disorders in HIV cohorts has raised
concern for subclinical atherosclerotic disease with impli-
cations on cognition. The large multicenter D:A:D study
and other groups have identified increased relative risk of
combined cerebrovascular and cardiovascular morbidity in
HIV subjects on cART [48]. HIV infection is associated
with cellular activation in a manner that may promote
atherosclerosis, and chronically infected cART-treated sub-
jects demonstrate endothelial dysfunction when compared
to controls [49, 50].
Few groups have demonstrated relationships between
atherosclerotic risk and cognition. The Multicenter AIDS
Cohort Study (MACS) identified a relationship between
carotid endothelial thickness and cognition [51]. Elevated
fasting glucose, insulin resistance and, separately, diabetes
correlated to poorer overall cognitive performance in the
Hawaii Aging with HIV Cohort (HAHC) study [52].
Using event-related electroencephalographic potentials, a
synergistic relationship between HIV and elevated BMI
was identified in a manner that suggests factors associated
with obesity exacerbate HIV-related frontal brain dys-
Fig. 1 Potential HIV-specific
mechanisms of central nervous
system (CNS) injury despite
combination antiretroviral thera-
py (cART). HIV virus infects
circulating monocytes, some of
which may cross the blood–
brain barrier in an activated
state. Immune activation may
result from intra and extra CNS
sources, including other periph-
eral reservoirs harboring HIV.
CNS virus may not be ade-
quately suppressed by cART
due to decreased CPE. These
mechanisms result in residual
infection and inflammation,
leading to astrocyte, macro-
phage, and microglial activation,
neuronal dysfunction, and
cognitive impairment
58 Curr HIV/AIDS Rep (2011) 8:54–61function [53]. In the multicenter SMART study (Strategies
for Management of Antiretroviral Therapy) where 88% of
the 292 subjects had undetectable plasma HIV RNA
levels, prior cardiovascular disease, hypercholesterolemia,
and hypertension were associated with poorer cognitive
performance [54].
Hepatitis C virus (HCV) is a frequent co-infection with
HIV. The interaction between HCV and HIV on cognition
has been controversial. Both viruses appear to invade CNS,
causing neurocognitive problems, with some studies noting
no exacerbation and others identifying interaction effects
[55, 56]. Noninfectious factors may also play a role. A
study from South Africa demonstrated increased risk for
HAND among individuals with post-traumatic stress
disorder and alcohol abuse [57]. There is also speculation
that antiretroviral medications themselves can contribute to
cognitive clouding in a manner that could contribute to
functional consequences. Among subjects with preserved
immune function, neurocognitive measures improved, as a
group, during treatment interruption in a small study of 167
subjects with good immune function [58], and neurological
imaging with MRS [59] and fMRI [60] suggests that certain
cART medications may have neurotoxic tendencies.
Although opportunistic infections continue to impact
HIV care internationally, broad cART access provides
opportunities to understand regional and subtype-specific
neuropathogenesis. Early data suggested heightened cogni-
tive risk associated with subtype B (most common in the
United States and Europe) [61]; however, recent findings
demonstrate a high prevalence in other settings where
subtype C is common [62]. Data from Uganda revealed that
cognitive impairment appeared to be more common among
patients infected with subtype D than with subtype A [63].
These findings are supported by in vitro studies, providing
a basis for the concept that differences by subtype could
uncover therapeutic targets [61, 64–66].
Conclusions: From Neuropathogenesis to Treatment
Cognitive impairment in HIV disease remains common,
despite effective cART. While symptoms are generally mild
and severe dementia is rare, the impairment impacts quality
of life and day-to-day functioning. Clinically relevant,
validated diagnostic screening tools are few, highlighting
an important unmet clinical need. Administering cARTwith
good adherence remains the single most effective means of
treating cognitive impairment in patients who are not on
treatment; yet, treatment alone has been unsuccessful in
eradicating HAND.
Important questions remain regarding optimal timing and
composition of cART to optimize CNS treatment and
preserve cognitive functioning. Studies evaluating adjuvant
therapies have been described elsewhere and have been
generally disappointing. A primary study of memantine did
not demonstrate efficacy, but more recent analyses of MRS
changes and results from the open-label phase of this study
were more promising [67, 68]. Reservoir-specific therapies
targeting monocytes or CNS directly may have utility, and
some new studies are underway. Nanoformulations of
antiretroviral drugs (nanoART) are being developed with
aims of improving drug delivery for CNS disorders [69].
Minimizing medication side effects, aggressive treatment of
cerebrovascular risk factors, assessment and treatment of
relevant co-infections and coexisting morbidities, physical
exercise, and social engagement are likely to provide some
benefit. While many of these recommendations are rooted
in observational studies of HAND or published reports
from other neurodegenerative diseases, they are not based
on randomized intervention trials.
There remain large areas of research need. Cohort studies
that focus on individuals with optimal peripheral control of
virus would better inform residual impairment despite cART.
Careful attention to the aging population that includes,
wheneverpossible,neuropathological-clinicalcorrelations,will
be critical to understanding pathology as this population ages
with chronic infection. Better clinical, imaging, and biomarker
tools to identify and categorize impairment in the clinical
setting are also required. Understanding the earliest changes to
brain function after infection may inform mechanisms in a
manner that could identify treatment targets.
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